Stock BIOR BIORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.6277 USD +3.41% Intraday chart for Biora Therapeutics, Inc. +2.07% -53.50%
Apr. 04 Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development CI
Apr. 03 Athyrium Capital Management Engages in Discussions with Biora Therapeutics CI

Business Summary

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Number of employees: 58

Sales per Business

USD in Million2022Weight2023Weight Delta
Molecular Testing Products
100.0 %
0 100.0 % 0 100.0 % -98.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -98.69%

Managers

Managers TitleAgeSince
Adi Mohanty CEO
 Chief Executive Officer 57 21-11-07
Eric d'Esparbes DFI
 Director of Finance/CFO 56 19-04-30
Ariella Kelman CTO
 Chief Tech/Sci/R&D Officer - 23-04-30
Paul W. Shabram CTO
 Chief Tech/Sci/R&D Officer - 22-04-24
Sharat Singh CTO
 Chief Tech/Sci/R&D Officer - -
Michael Rhode PRN
 Corporate Officer/Principal - -
Allison Luo PRN
 Corporate Officer/Principal 50 17-05-31
Robyn Hatton HRO
 Human Resources Officer - 13-07-31
Clarke Neumann LAW
 General Counsel 60 14-08-31

Members of the board

Members of the board TitleAgeSince
Jeffrey Allen Ferrell BRD
 Director/Board Member 49 14-05-31
Jeffrey Alter CHM
 Chairman 61 18-12-31
Adi Mohanty CEO
 Chief Executive Officer 57 21-11-07
Lynne Powell BRD
 Director/Board Member 57 19-01-31
Brian Kotzin BRD
 Director/Board Member 74 19-05-31
Jill Howe BRD
 Director/Board Member 48 21-11-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,292,111 35,588,352 ( 106.90 %) 0 106.90 %

Shareholders

NameEquities%Valuation
Athyrium Capital Management LP
70.95 %
19,306,283 70.95 % 21 M $
Athyrium Capital Management LP
40.17 %
10,929,762 40.17 % 12 M $
Adi Mohanty
5.658 %
1,539,492 5.658 % 2 M $
Armistice Capital LLC
3.950 %
1,074,895 3.950 % 1 M $
Eric d'Esparbes
2.219 %
603,662 2.219 % 664 028 $
Vanguard Group, Inc. (Subfiler)
1.867 %
507,935 1.867 % 558 729 $
Clarke Neumann
1.809 %
492,193 1.809 % 541 412 $
Geode Capital Management LLC
0.3419 %
93,038 0.3419 % 102 342 $
BlackRock Institutional Trust Co. NA
0.2391 %
65,051 0.2391 % 71 556 $
G1 Execution Services LLC
0.1869 %
50,849 0.1869 % 55 934 $
NameEquities%Valuation
Athyrium Capital Management LP
0.000000 %
0 0.000000 % - $

Company contact information

Biora Therapeutics, Inc.

4330 La Jolla Village Drive Suite 300

92122, San Diego

+833 727 2841

http://www.progenity.com
address Biora Therapeutics, Inc.(BIOR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Biora Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6277 USD
Average target price
10.3 USD
Spread / Average Target
+1,540.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIORA THERAPEUTICS, INC. Stock Biora Therapeutics, Inc.
-53.50% 22.52M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOR Stock
  4. Company Biora Therapeutics, Inc.